Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.

To be informative for chemoprevention, animal models must both closely emulate human disease and possess surrogate endpoint biomarkers that facilitate rapid drug screening. This study elucidated site-specific histopathological and biochemical surrogate endpoint biomarkers of spontaneous epidermal carcinogenesis in K14-HPV16 transgenic mice and demonstrated that the incidence and severity of these markers were decreased by the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO). The cumulative incidence of visible epidermal cancers in 127 untreated transgenic mice was 42% by 52 weeks of age, most frequently affecting the chest as flat lesions in association with chronic ulcers, or in the ear as protuberant masses. Microscopic malignancies were detected in 39% of 32-week-old transgenic mice and were found to emerge from precursor lesions that were of two distinct types: dysplastic sessile ear papillomas and hyperproliferative follicular/interfollicular chest dysplasias. ODC activity and tissue polyamine contents were differentially elevated in ear and chest skin during carcinogenesis, such that there was a marked elevation of both parameters of polyamine metabolism as early as 4 weeks of age in the ear, whereas in the chest, polyamine metabolism was increased significantly only in the late stages of neoplastic progression and in epidermal cancers. Administration of 1.0% DFMO in the drinking water from 4 to 32 weeks of age prevented both visible and microscopic malignancies and significantly decreased the incidence of chest and ear precursor lesions. ODC activity and tissue putrescine content were markedly diminished by DFMO chemoprevention in ear skin, whereas there was a more modest decline of these parameters in chest skin. DFMO treatment of transgenic mice from 28 to 32 weeks of age was associated with an absence of ear cancer and a marked regression of dysplastic papillomas. In contrast, the results in chest skin were complex in that the severity of chest precursors diminished, but their incidence was unchanged, and microscopic cancers were still detectable within these lesions. Collectively, this study highlights the utility of multistage epidermal carcinogenesis in K14-HPV16 transgenic mice both for the study of the biology of, and as a screening tool for, novel drugs and chemopreventive regimens.

[1]  Arbeit Jm.  Transgenic models of epidermal neoplasia and multistage carcinogenesis , 1996 .

[2]  G. Luk,et al.  α-Difluoromethylornithine-induced Inhibition of Growth of Autochthonous Experimental Colonic Tumors Produced by Azoxymethane in Male F344 Rats , 1988 .

[3]  L. Alhonen,et al.  Activation of Polyamine Catabolism Profoundly Alters Tissue Polyamine Pools and Affects Hair Growth and Female Fertility in Transgenic Mice Overexpressing Spermidine/SpermineN 1-Acetyltransferase* , 1997, The Journal of Biological Chemistry.

[4]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[5]  C. Danzin,et al.  Accumulation of decarboxylated S-adenosyl-L-methionine in mammalian cells as a consequence of the inhibition of putrescine biosynthesis. , 2005, European journal of biochemistry.

[6]  A. Balmain,et al.  The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted , 1998, Current Biology.

[7]  L. Chin,et al.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. , 1997, Genes & development.

[8]  J. Bickenbach.  Identification and behavior of label-retaining cells in oral mucosa and skin. , 1981, Journal of dental research.

[9]  Gerhard Christofori,et al.  A causal role for E-cadherin in the transition from adenoma to carcinoma , 1998, Nature.

[10]  T. Slaga,et al.  alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Verma,et al.  Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis. , 1987, Cancer research.

[12]  H. Thompson,et al.  Effect of D,L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. , 1986, Carcinogenesis.

[13]  R. Schlegel,et al.  Transgenic mice expressing targeted HPV-18 E6 and E7 oncogenes in the epidermis develop verrucous lesions and spontaneous, rasHa-activated papillomas. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[14]  D. Hanahan,et al.  Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Hanahan,et al.  Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. , 1996, The American journal of pathology.

[16]  M. Blessing,et al.  Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. , 1995, Cancer research.

[17]  T. Ratliff,et al.  Effects of α-Difluoromethylornithine and Recombinant Interferon-α2 on the Growth of a Human Renal Cell Adenocarcinoma Xenograft in Nude Mice , 1984 .

[18]  D. Hanahan,et al.  Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. , 1997, Cancer research.

[19]  G. Stoner,et al.  Cancer chemoprevention: principles and prospects. , 1993, Carcinogenesis.

[20]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Hanahan,et al.  Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. , 1996, Oncogene.

[22]  D. Hanahan,et al.  Dissecting multistep tumorigenesis in transgenic mice. , 1988, Annual review of genetics.

[23]  Rosenthal Sa.  Skin Carcinogenesis. Mechanisms and Human Relevance. , 1989 .

[24]  C. Potten,et al.  Epithelial stem cells in vivo , 1988, Journal of Cell Science.

[25]  V. Steele,et al.  Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. , 1994, Anticancer research.

[26]  A. J. Walhout,et al.  c-Myc/Max heterodimers bind cooperatively to the E-box sequences located in the first intron of the rat ornithine decarboxylase (ODC) gene. , 1997, Nucleic acids research.

[27]  E. Fuchs,et al.  Epidermal differentiation: the bare essentials , 1990, The Journal of cell biology.

[28]  G. Kelloff,et al.  Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. , 1996, Cancer research.

[29]  J. DiGiovanni,et al.  Multistage carcinogenesis in mouse skin. , 1992, Pharmacology & therapeutics.

[30]  C. Boone,et al.  Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention , 1993, Journal of cellular biochemistry. Supplement.

[31]  H. Mett,et al.  Stable Amplification of the S-Adenosylmethionine Decarboxylase Gene in Chinese Hamster Ovary Cells (*) , 1995, The Journal of Biological Chemistry.

[32]  D. Hanahan,et al.  The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. , 1996, Genes & development.

[33]  T G O'Brien,et al.  Polyamines regulate expression of the neoplastic phenotype in mouse skin. , 1998, Cancer research.

[34]  G. Kelloff,et al.  Chemoprevention of exprimental bladder cancer , 1992 .

[35]  R. Beauchamp,et al.  Inhibition of human gastric adenocarcinoma xenograft growth in nude mice by alpha-difluoromethylornithine. , 1988, Cancer research.

[36]  Jayashree,et al.  Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. , 1990, Cancer research.

[37]  E. Reddy,et al.  Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex. , 1993, The Journal of biological chemistry.

[38]  P. Jones.  Epithelial stem cells , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[39]  G. Mills,et al.  The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line. , 1993, Carcinogenesis.

[40]  R. Lotan,et al.  Chemoprevention trials and surrogate end point biomarkers in the cervix , 1995, Cancer.

[41]  Florence J. Reavis,et al.  High performance liquid chromatographic assay for alpha difluoromethylornithine in rodent feed , 1984 .

[42]  D. Hanahan,et al.  Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. , 1995, Oncogene.

[43]  T. Sun,et al.  Label-retaining cells reside in the bulge area of pilosebaceous unit: Implications for follicular stem cells, hair cycle, and skin carcinogenesis , 1990, Cell.

[44]  M. Takigawa,et al.  Polyamine biosynthesis and skin tumor promotion: inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin tumor formation by the irreversible inhibitor of ornithine decarboxylase alpha-difluoromethylornithine. , 1982, Biochemical and biophysical research communications.

[45]  V. Steele,et al.  Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program , 1994, Journal of cellular biochemistry. Supplement.

[46]  M. Loeffler,et al.  Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. , 1990, Development.

[47]  D. Roop,et al.  Dissecting molecular carcinogenesis: development of transgenic mouse models by epidermal gene targeting. , 1994, Advances in cancer research.

[48]  J. Sundberg,et al.  Squamous cell hyperplastic foci: precursors of cutaneous papillomas induced in SENCAR mice by a two-stage carcinogenesis regimen. , 1998, Cancer research.

[49]  V. Steele,et al.  Approaches to the development and marketing approval of drugs that prevent cancer. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[50]  G. Kelloff,et al.  Intermediate biomarkers of colon cancer: modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. , 1993, Carcinogenesis.

[51]  M. Bertagnolli,et al.  Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. , 1996, Cancer research.

[52]  D. Hanahan,et al.  Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice , 1994, Journal of virology.

[53]  T G O'Brien,et al.  Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. , 1997, Cancer research.

[54]  P. Greenwald.  Cancer risk factors for selecting cohorts for large‐scale chemoprevention trials , 1996, Journal of cellular biochemistry. Supplement.

[55]  T G O'Brien,et al.  Induction of ornithine decarboxylase in specific subpopulations of murine epidermal cells following multiple exposures to 12-O-tetradecanoylphorbol-13-acetate, mezerein and ethyl phenylpropriolate. , 1992, Carcinogenesis.

[56]  A. Pegg,et al.  Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. , 1988, Cancer research.

[57]  Hiroyuki Miyoshi,et al.  Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes , 1998, Cell.

[58]  P. Yaciuk,et al.  TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains , 1990, Cell.

[59]  S. Yuspa,et al.  Induction of papillomas with a high probability of conversion to malignancy. , 1985, Carcinogenesis.